AbbVie (ABBV)
NYSE: ABBV · Pharmaceuticals · North Chicago, IL
Our rating: Neutral
Call changed from Positive to Neutral at $294.83, moderate conviction, November 4, 2026.
Breaks if: The Neutral call turns Positive if revenue growth accelerates to 12% or above in two consecutive reported quarters within the next 12 months while free cash flow holds at or above $17 billion on a trailing annual basis. It turns Cautious if revenue growth falls to below 4% year over year for two consecutive reported quarters, or if trailing twelve-month free cash flow drops below $13 billion in any reported period.
Key figures
| Market value | $505.9B |
|---|---|
| Revenue, last 12 months | $66.0B |
| Net income, last 12 months | $10.3B |
| Free cash flow, last 12 months | $18.9B |
| Price to earnings | 48.9× |
| Free cash flow yield | 3.7% |
| Dividend yield | 2.4% |
| Operating margin | 32.2% |
| Return on equity | n/a |
| Beta to the S&P 500 | 0.24 |
| Volatility, annualized | 26.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $17.4B | 10.3% | $2.37 | $7.3B |
| June 30, 2026 | $17.0B | 10.2% | $2.03 | $3.1B |
| March 31, 2026 | $15.0B | 12.4% | $0.39 | $3.6B |
| December 31, 2025 | $16.6B | 10.0% | $1.02 | $4.9B |
| September 30, 2025 | $15.8B | 9.1% | $0.10 | $6.6B |
| June 30, 2025 | $15.4B | 6.6% | $0.52 | $4.9B |
| March 31, 2025 | $13.3B | 8.4% | $0.72 | $1.4B |
| December 31, 2024 | $15.1B | 5.6% | $-0.02 | $6.8B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $18.4B: Claude 62%, Gemini 85%, Mistral 50%
- Diluted earnings per share are at least $1.02: Claude 55%, Gemini 75%, Mistral 70%
- Free cash flow for the quarter is at least $4.89B: Claude 52%, Gemini 65%, Mistral 55%
15 ledger entries and 40 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.